Sarcoidosis manifesting during treatment with secukinumab for psoriatic arthritis

Sarcoidosis is a multisystem inflammatory disorder of uncertain aetiology. There are numerous case reports of sarcoidosis occurring during treatment with biological immunotherapies. Here, we describe the case of a 52-year-old woman with psoriatic arthritis who developed multisystem sarcoidosis while...

Full description

Saved in:
Bibliographic Details
Published in:BMJ case reports 2021-02, Vol.14 (2), p.e240615
Main Authors: Kirby, Colm, Herlihy, Darragh, Clarke, Lindsey, Mullan, Ronan
Format: Article
Language:English
Subjects:
Antibodies, Monoclonal - adverse effects
Antibodies, Monoclonal, Humanized - adverse effects
Arthritis
Arthritis, Psoriatic - drug therapy
Biopsy
Case Report
Case reports
Cytokines
Disease
Female
Humans
Immunotherapy
Inflammatory diseases
Laboratories
Lymphatic system
Middle Aged
Monoclonal antibodies
Psoriasis
Psoriatic arthritis
Sarcoidosis
Sarcoidosis - chemically induced
Sarcoidosis - diagnosis
Sarcoidosis - drug therapy
Skin
Tumor necrosis factor-TNF
Ultrasonic imaging
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sarcoidosis is a multisystem inflammatory disorder of uncertain aetiology. There are numerous case reports of sarcoidosis occurring during treatment with biological immunotherapies. Here, we describe the case of a 52-year-old woman with psoriatic arthritis who developed multisystem sarcoidosis while being treated with secukinumab (anti-interleukin-17A) therapy which, to our knowledge, is the first such case. We discuss existing literature and hypothesise that IL-17 blockade may precipitate the development of granulomatous disease.
ISSN:1757-790X
1757-790X
DOI:10.1136/bcr-2020-240615